Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States

Hideki Maeda, Tatsuo Kurokawa

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States'. Together they form a unique fingerprint.

Medicine & Life Sciences